MedTrace Logo

Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

NCT02303847 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-05-27

No results posted yet for this study

Summary

This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.

Conditions

Interventions

DRUG

Ketamine

ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.

Sponsors & Collaborators

Principal Investigators

  • Lucinda Grande, MD · University of Washington Department of Family Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303847 on ClinicalTrials.gov